Detalles de la búsqueda
1.
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
Lancet
; 403(10435): 1460-1471, 2024 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38554725
2.
Development and validation of a patient reported experience measure for experimental cancer medicines (PREM-ECM) and their carers (PREM-ECM-Carer).
BMC Cancer
; 24(1): 500, 2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38641809
3.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Oncologist
; 28(4): 333-340, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36576173
4.
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.
Cancer Immunol Immunother
; 72(4): 805-814, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36315268
5.
Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell Therapy.
J Biomed Inform
; 142: 104367, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37105509
6.
Enrolment of older adults with cancer in early phase clinical trials-an observational study on the experience in the north west of England.
Age Ageing
; 50(5): 1736-1743, 2021 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34107012
7.
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
Oncologist
; 25(1): 55-63, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31292268
8.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 20(8): 1124-1135, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31257177
9.
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncol
; 20(3): 383-393, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745090
10.
T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.
Curr Opin Oncol
; 31(5): 430-438, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31335828
11.
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Lancet Oncol
; 19(4): 451-460, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29530667
12.
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Cancer Immunol Immunother
; 66(11): 1425-1436, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28660319
13.
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.
Cancer Immunol Immunother
; 63(2): 133-45, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24190544
14.
Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives.
BMJ Open
; 14(3): e075547, 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38508621
15.
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Cancer Med
; 13(5)2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38501219
16.
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review.
Pharmacoeconomics
; 41(6): 675-692, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36905571
17.
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.
EJHaem
; 4(3): 882-885, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37601889
18.
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
J Clin Oncol
; 41(14): 2493-2502, 2023 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809050
19.
Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Am J Cancer Res
; 12(8): 3967-3984, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36119832
20.
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Clin Immunol
; 138(1): 85-96, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21056008